C0671  BBAP, A Novel Zinc Finger Protein Which Co-associates with the Risk-Related BAL Gene in B-Cell Lymphomas (US20020120112A1)
Margaret Shipp, M.D.

C0704  Methods and Compositions for the Diagnosis of Cancer Susceptibilities and Defective DNA Repair Mechanisms and Treatment Thereof (PCT/US2002/018153)
Alan D’Andrea, M.D.

Kornelia Polyak, M.D., Ph.D.

C0764  MUC-1 Extracellular Domain and Cancer Treatment Compositions and Methods Derived therefrom (PCT/US2001/028548)
Donald Kufe, M.D.

C0853  Gene Expression in Breast Cancer (PCT/US2004/008866)
Kornelia Polyak, M.D., Ph.D.

C1023  A Fragment of Fibrinogen Alpha as a Marker for Diagnosis and Therapy Monitoring in Breast Cancer (US8318441)
J. Dirk Iglehart, M.D.

C1027  Methods of Detecting Ovarian Cancer: Elafin as Diagnostic and Prognostic Biomarker (US8486648)
David Livingston, M.D.  Ronny Drapkin, M.D.

C1079  Inhibitors of USP1 Deubiquitinating Enzyme Complex (PCT/US2007/014378)
Alan D’Andrea, M.D.

C1143  A Kinome-wide Activation of Kinases by Myristoylation (US8178317)
Thomas Roberts, Ph.D.  Jean Zhao, Ph.D.

C1238  Exploiting the Chk1-Suppressed Pathway and its Associated Biomarker (PCT/US2009/000702)
Thomas A Look, M.D.

C1250  Compositions for Detecting Cell Death and Methods of use Thereof (PCT/US2009/004380)
Andrew L. Kung, M.D., Ph.D.

For more information, please contact the Innovation Office at DFCI:
innovation@dfci.harvard.edu
Diagnostic & Biomarker Opportunities

C1542  Methods for Treating, Preventing and Predicting Risk of Developing Breast Cancer (PCT/US2013/032384)
Kornelia Polyak, M.D., Ph.D.

C1548  Methods for Generating Nucleic Acid Molecule Fragments Having a Customized Size Distribution (PCT/US2014/024598)
Keith Ligon, M.D., Ph.D.

C1613  Metabolomic Profiling defines Oncogenes Driving Prostate Tumors (PCT/US2013/073569)
Massimo Loda, M.D.

C1650  Metabolic Profiling in Tissue and Serum Indicative of Tumor Differentiation in Prostate Cancer (PCT/US2013/069153)
Massimo Loda, M.D.

C1658  Peripheral Blood Circulating miRNA as Biomarkers of Prognosis in Cancer (PCT/US2013/068093)
Irene Ghobrial, M.D.

C1711  Non-invasive Blood Based Monitoring of Genomic Alterations in Cancer (PCT/US2014/041871)
Cloud Paweletz, Ph.D. ♦ Geoffrey Oxnard, M.D.

C1725  Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators (PCT/US2014/038938)
Andrew Lane, M.D., Ph.D. ♦ David Weinstock, M.D.

C1764  A diagnostic galectin-1 monoclonal antibody (PCT/US2014/047783)
Margaret Shipp, M.D.

C1781  Detecting Human PD-L1 Expression using Novel PD-L1 Monoclonal Antibodies Targeting the Cytoplasmic Domain (PCT/US2014/062149)
Gordon Freeman, Ph.D.

For more information, please contact the Innovation Office at DFCI:
innovation@dfci.harvard.edu
Diagnostic & Biomarker Opportunities

C1807  PDL1 as a Biomarker (PCT/US2015/011303)  
F. Stephen Hodi, M.D.

C1834, C1835, C1836 High Affinity PD-1, PD-L1, PD-L2 Monoclonal Antibodies for Diagnostics  
Gordon Freeman, Ph.D.

C1841  Utilizing Total number of Genome-wide Mutations and status of the BRCA1 and/or BRCA2 to predict Clinical Outcome in Ovarian Cancer (US14682545)  
J. Dirk Iglehart, M.D.

C1871  Measurement of PD-1 Pathway Activation using an Anti-phosphotyrosine PD-1 mAb  
Gordon Freeman, Ph.D.

C1880  Novel Biomarker for Sensitivity to PD-L1 Targeted Therapy (PCT/US2015/032823)  
Kwok-Kin Wong, M.D., Ph.D.  •  David Barbie, M.D.

C1890  ERK1 and ERK2 Mutants that Confer Resistance to RAF/MEK or ERK Inhibitors (PCT/US2015/035337)  
Levi Garraway, M.D., Ph.D.

F. Stephen Hodi, M.D.
Diagnostic & Biomarker Opportunities

F. Stephen Hodi, M.D.

C1971  Serum microRNAs as Biomarkers of Survival After Radiation (PCT/US2016/017187)
Dipanjan Chowdhury, Ph.D.

C2032  Composition and Methods for Diagnosing Prostate Cancer using Stromal (bone) Homing Signature (Provisional Filed)
Massimo Loda, M.D.

C2042  Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle Invasive Urethelial Carcinoma (PCT/US2015/021014)
Levi Garraway, M.D., Ph.D. • Eliezer Van Allen, M.D.

C2092  A Biomarker of Docetaxel Resistance in Prostate Cancer (Provisional File)
Christopher Sweeney, MBBS

C2093  A Biomarker of Lethal Prostate Cancer (Provisional Filed)
Christopher Sweeney, MBBS

C2149  Compositions and Methods for Screening Pediatric Gliomas (Provisional Filed)
Rameen Beroukhim, M.D., Ph.D.

C2269  Serum MicroRNA Sequencing for Early Diagnosis of Invasive Ovarian Cancer (Provisional Filed)
Dipanjan Chowdhury, Ph.D.

For more information, please contact the Innovation Office at DFCI:
innovation@dfci.harvard.edu